April 12th 2024
Sarah Lee, MD, MBA, discussed a study to better disaggregate the subgroup of Asian American patients with ovarian cancer.
Community Practice Connections™: Real-World Applications of Novel Therapies Across TNBC and Addressing Disparities in Care
View More
Advances in TNBC: Communicating with Your Patients About Clinical Trial Awareness and Treatment Concerns to Improve Clinical Outcomes
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Early Research Under Way to Improve Drug Delivery in Ovarian Cancer
February 10th 2015Targeted agents have become available in recent years to treat many major cancers, but for women with ovarian cancer, standard treatment following cytoreductive surgery remains systemic intravenous/intraperitoneal chemotherapy with a platinum agent and a taxane. Approximately 80% of women who receive first-line treatment with this platinum-based regimen experience relapsed disease. However, early research indicates that more and better options may be on the way.
Read More
BioT3 Integrates Diagnosis With Actionable Biomarkers in Metastatic Cancer
January 28th 2015Metastatic disease accounts for the vast majority of cancer-related deaths. Ensuring a definitive diagnosis and the most effective treatment in a timely fashion is essential for extending life expectancy.
Read More
New York State Awards Grant for First Stem-Cell Immunotherapy Trial in Ovarian Cancer
January 16th 2015The New York State Stem Cell Science Program recently awarded a 4-year $11.9 million grant to Roswell Park Cancer Institute to fund research and development of a stem-cell based treatment for ovarian cancer.
Read More
Ovarian Suppression Lowers Risk of Recurrence in Younger, Premenopausal Breast Cancer Patients
December 12th 2014Women with HR+ breast cancer who remained premenopausal after receiving chemotherapy had a lower risk of disease recurrence when adding ovarian suppression to adjuvant exemestane or—to a lesser extent—tamoxifen, compared with standard tamoxifen alone.
Read More
Cirmtuzumab Blocks Ovarian Cancer Metastasis in Preclinical Study
November 18th 2014The monoclonal antibody cirmtuzumab, currently in clinical trials to treat CLL, targets ROR1 on the surface of cancerous B cells, and the agent may have a wider reach in the treatment of ovarian and other cancers.
Read More
Molecular Discoveries Yield Many Personalized Treatment Targets in Ovarian Cancer
November 7th 2014Translating current and emerging knowledge of the molecular drivers of ovarian cancer is yielding promising new insights into potential clinical targets, moving treatment away from historical paradigms in favor of more personalized therapeutic approaches.
Read More
The State of PARP Inhibitors in Ovarian Cancer: Many Agents, Many Questions
November 7th 2014PARP inhibitors represent an important class of emerging therapies for the treatment of patients with ovarian cancer and possibly other malignancies, but many scientific questions about the underlying molecular mechanisms that these agents target must be answered before they can be fully employed in clinical practice.
Read More
Trebananib Does Not Improve Survival in Ovarian Cancer
November 5th 2014A statistically significant improvement in overall survival (OS) was not seen with the combination of paclitaxel and the angiogenesis inhibitor trebananib when compared with paclitaxel alone for patients with recurrent platinum-resistant ovarian cancer.
Read More
Novel Combination May Extend Survival in Ovarian Cancer
October 17th 2014Two agents with contrasting mechanisms of actions exert synergistic effects while limiting tumor blood supply in ovarian cancer. Patient enrollment began this month (October 2014) for a new phase 1b/2 clinical study1 to evaluate this novel combination with the VDA fosbretabulin plus pazopanib.
Read More
Lasker Winner Recommends Widespread Screening for Ovarian and Breast Cancer
September 25th 2014Mary-Claire King, PhD, the researcher who identified BRCA1's linkage to hereditary breast and ovarian cancer, was announced as the winner of the 2014 Lasker~Koshland Special Achievement Award in Medical Science.
Read More
On The Horizon for Ovarian Cancer: Potentially Promising Treatments
September 25th 2014Most patients with ovarian cancer present with bulky and metastatic disease. Surgery and platinum-based chemotherapies are the mainstay of treatment for newly diagnosed disease, but recurrence/resistance are common.
Read More
Veliparib Demonstrates Clinical Activity in Patients with BRCA-Positive Breast, Ovarian Tumors
September 6th 2014The poly (ADP-ribose) polymerase (PARP) inhibitor veliparib exhibits antitumor activity and is safe and tolerable on a continuous dosing schedule when used for the treatment of patients with BRCA-positive and BRCA-wild type tumors.
Read More
Several MAGE Antigens Proposed as Targets for Epithelial Ovarian Cancer Immunotherapy
August 18th 2014A new study has recommended priority targets for immunotherapy in epithelial ovarian cancer (EOC) by profiling the expression of certain tumor-associated antigens (TAA), called MAGE cancer-testis antigens (CTA), in a large panel of tumor samples.
Read More